High dose anakinra for treatment of severe neonatal Kawasaki disease: A case report

Pediatric Rheumatology

Volumn 12, Issue 1, 2014, Pages

  Shafferman, Ashley ^a   Birmingham, James D ^b   Cron, Randy Q ^c  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Anakinra; Interleukin 1 receptor antagonist; Kawasaki disease; Macrophage activation syndrome; Neonate; Secondary hemophagocytic lymphohistiocytosis

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FERRITIN; GRANZYME B; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; PERFORIN; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CASE REPORT; CHAPPED LIPS; CONJUNCTIVITIS; COUGHING; DIARRHEA; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HUMAN; INFANT; MACROPHAGE ACTIVATION SYNDROME; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; DRUG MONITORING; EARLY DIAGNOSIS; EARLY INTERVENTION; PATHOPHYSIOLOGY; PATIENT ACUITY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; EARLY MEDICAL INTERVENTION; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MACROPHAGE ACTIVATION SYNDROME; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATIENT ACUITY; TREATMENT OUTCOME;

EID: 84904078509     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-12-26     Document Type: Article

References (29)

1. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, . Committee on Rheumatic Fever, Endocarditis, and KawasakiDisease Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004, 114:1708-1733. Committee on Rheumatic Fever, Endocarditis, and KawasakiDisease.
2. Anderson MS, Burns J, Treadwell TA, Pietra BA, Glode MP. Erythrocyte sedimentation rate and C-reactive protein discrepancy and high prevalence of coronary artery abnormalities in Kawasaki disease. Pediatr Infect Dis J 2001, 20:698-702.
3. Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, Meissner C, Bastian J, Beiser AS, Meyerson HM, Newburger JW. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr 1991, 118:680-686.
4. Shike H, Kanegaye JT, Best BM, Pancheri J, Burns JC. Pyuria associated with acute Kawasaki disease and fever from other causes. Pediatr Infect Dis J 2009, 28:440-443.
5. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996, 94:1379-1385.
6. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008, 153:833-838.
7. Venugopalan P, Jaya S, Al-Azri MA, Piopongco E. Kawasaki disease resistant to immunoglobulin G therapy. Ann Trop Paediatr 2003, 23:187-191.
8. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002, 14:548-552.
9. Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, Magni-Manzoni S, Insalaco A, Cortis E, van Solinge WW, Prakken BJ, Wulffraat NM, de Benedetti F, Kuis W. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010, 49:441-449.
10. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012, 13:289-298.
11. Sullivan KE, Delaat CA, Douglas SD, Filipovich AH. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res 1998, 44:465-468.
12. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008, 50:1227-1235.
13. Latino GA, Manlhiot C, Yeung RS, Chahal N, McCrindle BW. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 2010, 32:527-531.
14. Kahn PJ, Cron RQ. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol 2013, 40:743-744.
15. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011, 50:417-419.
16. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008, 4:615-620.
17. Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. J Rheumatol 2010, 37:879-880.
18. Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, Zuiderveen S, Birmingham J. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically Ill children. Pediatr Crit Care Med 2014, 15:401-408.
19. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. Development and validation of a score for the diagnosis of reactive hemophagocytic syndrome (HScore). Arthritis Rheumatol 2014, Epub ahead of print.
20. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007, 34:1133-1138.
21. Kang HR, Kwon YH, Yoo ES, Ryu KH, Kim JY, Kim HS, Kim HM, Lee YH. Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease. Blood Res 2013, 48:254-257.
22. Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri J, Tremoulet AH, Watson VE, Best BM, Burns JC. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009, 123:e783-e789.
23. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001, 85:421-426.
24. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med 2012, 63:233-246.
25. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G, . Histocyte Society Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002, 100:2367-2373. Histocyte Society.
26. Cohen S, Tacke CE, Straver B, Meijer N, Kuipers IM, Kuijpers TW. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann Rheum Dis 2012, 71:2059-2061.
27. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010, 62:258-267.
28. Sonoda K, Mori M, Hokosaki T, Yokota S. Infliximab Plus Plasma Exchange Rescue Therapy in Kawasaki Disease. J Pediatr 2014, 164:1128-1132.
29. Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 2014, 383:1731-1738.